Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation HAYES, Inc. Magnetic resonance imaging–guided in-bore biopsy for prostate cancer. Lansdale: HAYES, Inc. Directory Publication. 2017 Authors' conclusions Rationale:
Targeted magnetic resonance imaging (MRI)-guided biopsy techniques, such as MRI-guided in-bore (MRI-IB) biopsy, have been developed to increase identification of clinically significant prostate cancer without increasing the detection of clinically nonsignificant tumors.
Technology Description:
MRI-IB biopsy is a technique that uses MRI images captured in real time and processed by interventional planning software to help insert and confirm the location of biopsy needles into target lesions suspected to be prostate cancer as previously identified by multiparametric MRI (mpMRI).
Controversy:
MRI-IB biopsies require more resources than systematic 12-core transrectal ultrasonography (TRUS) biopsy. It is currently unclear whether MRIIB biopsy consistently detects clinically significant cancer at a higher rate than systematic TRUS biopsy, and if the use of these additional resources is warranted.
Key Questions:
Does MRI-IB biopsy provide accurate diagnostic and/or staging information for men with suspected or diagnosed prostate cancer? Does use of MRI-IB biopsy improve patient management or outcomes? Is MRI-IB
biopsy safe? Have definitive patient selection criteria been established for MRI-IB-biopsy? Indexing Status Subject indexing assigned by CRD MeSH Biopsy; Humans; Magnetic Resonance Imaging; Male; Prostatic Neoplasms Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32018000107 Date abstract record published 15/02/2018 |